Disease Control Data, nr-axSpA

Review separate clinical trial data relating to the efficacy of RINVOQ® in non-radiographic axial spondyloarthritis patients. See Important Safety Info, including BOXED WARNING, and full Prescribing Info.

FDA Approval Of The First nr-AxSpA Biologics Projecting Regulatory Market Dynamics

One-quarter of patients with axial SpA remain flare-free after ceasing etanercept

Radiographic axial versus nonradiographic axial spondyloarthritis: Comparison of the disease activity parameters and the disease activity and functional scores: RBSMR study

Comparison of Men and Women With Axial Spondyloarthritis in the US-based Corrona Psoriatic Arthritis/Spondyloarthritis Registry

Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis

Building a Treatment Plan for active Non-radiographic Axial Spondyloarthritis (nr-axSpA)

Axial spondyloarthritis: concept, construct, classification and implications for therapy

Treat-to-target in axial spondyloarthritis — what about physical function and activity?

Sustained low disease activity measured by ASDAS slow radiographic spinal progression in axial spondyloarthritis patients treated with TNF-inhibitors: data from REGISPONSERBIO, Arthritis Research & Therapy

Monthly improvements in paid work productivity: ankylosing spondylitis

Abbreviations AS: ankylosing spondylitis; ASAS: Assessment of

IJMS, Free Full-Text

Axial Spondyloarthritis RINVOQ® (upadacitinib)